Salud financiera de hoja de balance de Lincoln Pharmaceuticals
Salud financiera controles de criterios 6/6
Lincoln Pharmaceuticals tiene un patrimonio de accionistas total de ₹5.9B y una deuda total de ₹10.7M, lo que sitúa su ratio deuda-patrimonio en 0.2%. Sus activos y pasivos totales son ₹7.0B y ₹1.1B respectivamente. El BAIT de Lincoln Pharmaceuticals es de ₹906.2M, por lo que su ratio de cobertura de intereses es de 60.9. Tiene efectivo e inversiones a corto plazo que ascienden a ₹1.5B.
Información clave
0.2%
Ratio deuda-patrimonio
₹10.67m
Deuda
| Ratio de cobertura de intereses | 60.9x |
| Efectivo | ₹1.53b |
| Patrimonio | ₹5.93b |
| Total pasivo | ₹1.07b |
| Activos totales | ₹7.00b |
Actualizaciones recientes sobre salud financiera
Does Lincoln Pharmaceuticals (NSE:LINCOLN) Have A Healthy Balance Sheet?
Mar 15
Is Lincoln Pharmaceuticals (NSE:LINCOLN) A Risky Investment?
Nov 05Recent updates
Do Lincoln Pharmaceuticals' (NSE:LINCOLN) Earnings Warrant Your Attention?
Sep 06Lincoln Pharmaceuticals Limited's (NSE:LINCOLN) Business And Shares Still Trailing The Market
Mar 14Does Lincoln Pharmaceuticals (NSE:LINCOLN) Deserve A Spot On Your Watchlist?
Nov 04Lincoln Pharmaceuticals' (NSE:LINCOLN) Dividend Will Be ₹1.50
Sep 14Lincoln Pharmaceuticals (NSE:LINCOLN) Is Paying Out A Dividend Of ₹1.50
Aug 31Lincoln Pharmaceuticals' (NSE:LINCOLN) Dividend Will Be ₹1.50
Sep 12Lincoln Pharmaceuticals (NSE:LINCOLN) Is Due To Pay A Dividend Of ₹1.50
Aug 29If You Like EPS Growth Then Check Out Lincoln Pharmaceuticals (NSE:LINCOLN) Before It's Too Late
Feb 14Should You Be Adding Lincoln Pharmaceuticals (NSE:LINCOLN) To Your Watchlist Today?
Aug 16Here's Why I Think Lincoln Pharmaceuticals (NSE:LINCOLN) Is An Interesting Stock
May 06Is Lincoln Pharmaceuticals Limited (NSE:LINCOLN) A Smart Choice For Dividend Investors?
Apr 03Does Lincoln Pharmaceuticals (NSE:LINCOLN) Have A Healthy Balance Sheet?
Mar 15Could The Market Be Wrong About Lincoln Pharmaceuticals Limited (NSE:LINCOLN) Given Its Attractive Financial Prospects?
Feb 28Insider Buying: The Lincoln Pharmaceuticals Limited (NSE:LINCOLN) Whole Time Director Just Bought 15% More Shares
Feb 12Does Lincoln Pharmaceuticals (NSE:LINCOLN) Deserve A Spot On Your Watchlist?
Feb 01
Lincoln Pharmaceuticals (NSE:LINCOLN) Shareholders Booked A 27% Gain In The Last Five Years
Jan 19Trade Alert: The Whole Time Director Of Lincoln Pharmaceuticals Limited (NSE:LINCOLN), Munjal Patel, Has Just Spent ₹20m Buying 9.2% More Shares
Jan 06Why Lincoln Pharmaceuticals Limited (NSE:LINCOLN) Is A Dividend Rockstar
Dec 27Lincoln Pharmaceuticals's (NSE:LINCOLN) Earnings Are Growing But Is There More To The Story?
Dec 14Have Insiders Been Buying Lincoln Pharmaceuticals Limited (NSE:LINCOLN) Shares This Year?
Dec 01Declining Stock and Solid Fundamentals: Is The Market Wrong About Lincoln Pharmaceuticals Limited (NSE:LINCOLN)?
Nov 18Is Lincoln Pharmaceuticals (NSE:LINCOLN) A Risky Investment?
Nov 05Análisis de la situación financiera
Pasivos a corto plazo: Los activos a corto plazo (₹4.5B) de LINCOLN superan a sus pasivos a corto plazo (₹922.8M).
Pasivo a largo plazo: Los activos a corto plazo de LINCOLN (₹4.5B) superan a sus pasivos a largo plazo (₹151.8M).
Historial y análisis de deuda-patrimonio
Nivel de deuda: LINCOLN tiene más efectivo que su deuda total.
Reducción de la deuda: El ratio deuda-patrimonio de LINCOLN ha pasado de 11.8% a 0.2% en los últimos 5 años.
Cobertura de la deuda: La deuda de LINCOLN está bien cubierta por el flujo de caja operativo (8899.6%).
Cobertura de intereses: Los pagos de intereses de la deuda de LINCOLN están bien cubiertos por el BAIT (84.4x cobertura).